Clinical Study
Bone Loss after Allogeneic Haematopoietic Stem Cell Transplantation: A Pilot Study on the Use of Zoledronic Acid
Table 2
Percentual BMD increase (%) of femur hip-significant and nonsignificant parameters (BMD group
).
| | | | 1 year | 2 years | | | | | | 1 year | 2 years |
| | Age | <45 years | 16 | 8.9 | 12.0 | 0.007 | 0.02 | | ≥45 years | 10 | 2.9 | 3.4 | | Donor gender | Female | 14 | 7.6 | 10.2 | 0.04 | 0.05 | | Male | 12 | 2.9 | 4.4 | | Immunosuppression | CSA/MTX | 18 | 7.1 | 9.3 | 0.01 | 0.02 | | CSA/MMF | 8 | 2.2 | 3.9 | | Gender | Male | 18 | 6.5 | 8.6 | — | — | | Female | 8 | 3.5 | 5.4 | — | — | | BMD | Osteopenia | 13 | 5.5 | 7.8 | — | — | | Osteoporosis | 13 | 9.6 | 7.8 | — | — | | Prior steroids | Yes | 20 | 5.9 | 8.2 | — | — | | No | 6 | 4.3 | 5.5 | — | — | | Steroids during study | Yes | 20 | 5.3 | 8.8 | — | — | | No | 6 | 5.6 | 7.2 | — | — | | Diagnosis | CML | 8 | 5.5 | 6.7 | — | — | | AML | 11 | 4.7 | 6.6 | — | — |
|
|
(—) Not significant.
|
